Study CB-839 in Combination With Nivolumab in Patients With Melanoma ccRCC and NSCLC
This study is an open-label Phase 1/ 2 evaluation of CB-839 in combination with nivolumab in patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
- ClinicalTrials.gov Identifier: NCT02771626
- Protocol Number: 16-379
- Principal Investigator: David McDermott
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required